Drug treatment of depression

Western Journal of Medicine

Volumn 171, Issue 2, 1999, Pages 102-105

  Martensson, Bjorn ^a   Spigset, Olav ^b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0003887050     PISSN: 00930415     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Martensson B. Depressive illness and the possibilities of somatic antidepressant treatment. Int J Technol Assess Health Care 1996;12:554-572.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disoreters. 4th ed. Washington, DC: APA; 1994.
3. Frank E, Karp JF, Rush AJ. Efficacy of treatments for major depression. Psychopharmacol Bull 1993;29:457-475.
4. Weiss M, Gaston L, Propst A, et al. The role of the alliance in the pharmacologic treatment of depression. J Clin Psychiatry 1997;58:196-204.
5. Dunlop SR, Dornseif BE, Wernicke JF, Potvin JH. Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression. Psychopharmacol Bull 1990;26:173-180.
6. Lima MS, Moncrieff J. A comparison of drugs versus placebo for the treatment of dysthymia: a systematic review. In: Cochrane Collaboration. Cochrane Library. Oxford: Update Software; 1998. (www.update-sofrware.com/ccweb/cochrane/ revabstr/ab001130.htm)
7. Trindade E, Menon D. Selective serotonin reuptake inhibitors (SSRIs) for major depression. Part 1: evaluation of the clinical literature [report 3E]. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 1997.
8. Anderson IM. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depression Anxiety 1998;7(suppl 1):11-7.
9. Danish University Antidepressant Group (DUAG). Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology 1986;90:131-138.
10. Danish University Antidepressant Group (DUAG). Paroxetine: a selective serotonin reuptake inhibitor showing a better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affective Disord 1990;18:289-299.
11. Danish University Antidepressant Group (DUAG). Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affective Disord 1993;28:105-116.
12. Burnett FE, Dinan TG. The clinical efficacy of venlafaxine in the treatment of depression. Rev Contemp Pharmacother 1998;9:303-20.
13. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997;23:176-194.
14. Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995;56(suppl 6):12-21.
15. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994;164:549-550.
16. Martin RM, Hilton SR, Kerry SM, Richards NM. General practitioners' perceptions of the tolerability of antidepressant drug: a comparison of selective serotonin reuptake inhibitors and tricyclic antidepressants. BMJ 1997;314:646-651.
17. Donoghue JM, Tylee A. The treatment of depression: prescribing patterns of antidepressants in primary care in the UK. Br J Psychiatry 1996;168:164-168.
18. Kasper S, Bech P, de Jonghe F, et al. Treatment of unipolar major depression: algorithms for pharmacotherapy. Int J Psychiatry Clin Pract 1997;1:55-57.
19. Bertilsson L, Dahl, M-L. Polymorphic drug oxidation: relevance to the treatment of psychiatric disorders. CNS Drugs 1996;3:200-223.
20. Nelson JC. Treatment of antidepressant nonresponders: augmentation or switch? J Clin Psychiatry 1998;59:(suppl 15):35-41.
21. Rouillon F, Gorwood P. The use of lithium to augment antidepressant medication. J Clin Psychiatry 1998;59(suppl 5):32-39.
22. Aronson R, Offman HJ, Joffe RT, Naylor CD. Tri-iodothyronine augmentation in the treatment of refractory depression. Arch Gen Psychiatry 1996;53:842-848.
23. McAskill R, Mir S, Taylor D. Pindolol augmentation of antidepressant therapy. Br J Psychiatry 1998;173:203-208.
24. Thase ME, Sullivan LR. Relapse and recurrence of depression: a practical approach for prevention. CNS Drugs 1995;4:261-277.
25. Paykel ES. Remission and residual symptomatology in major depression. Psychopathology 1998;31:5-14.
26. Dilsaver SC. Withdrawal phenomena associated with antidepressant and antipsychotic agents. Drug Safety 1994;10:103-114.
27. Haddad P, Lejoyeux M, Young A. Antidepressant discontinuation reactions. BMJ 1998;316:1105-1106.
28. Terra JL, Montgomery SA. Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. Int Clin Psychopharmacology 1998;13:55-62.
29. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-320.
30. Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacology 1997;17:208-221.
31. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010-1015.
32. Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. Obster Gynecol 1997;89:713-718.
33. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors, JAMA 1998;279:609-610.
34. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997;336:258-262.
35. Spigset O, Hågg S. Excretion of psychotropic drugs into breast milk. CNS Drugs 1998;9:111-134.
36. Crott R, Gilis P. Economic comparisons of the pharmacotherapy of depression: an overview. Acta Psychiatr Scand 1998;97:241-252.